Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 240

Sort by

Sort Order Select

Journal Articles

YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia

Shuhong Hu, Yifei Liu, Xiang Zhang, Xiaoqi Wang, Yanting Li, Mengqian Chu, Jie Yin, Yanglan Fang, Changgeng Ruan, Li Zhu, Depei Wu, Yang Xu

Blood (2024) 144 (20): 2136–2148.

https://doi.org/10.1182/blood.2023023601

Published: 2024

Includes: Supplemental data

Journal Articles

Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

Blood (2024) 144 (Supplement 1): 971.

https://doi.org/10.1182/blood-2024-202801

Published: 2024

Journal Articles

Risk Factors and Prediction Model for Long-Term Survival of Ⅲ-Ⅵ Steroid-Refractory Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation

Yaxue Wu, Xiaohui Hu, Depei Wu, Shanshan Jiang, Yuanbing Wu

Blood (2024) 144 (Supplement 1): 7360.

https://doi.org/10.1182/blood-2024-203523

Published: 2024

Journal Articles

Preliminary Investigation of the Efficacy and Safety of Zanubrutinib in Combination with R-Chemo As First-Line Therapy Inpatients with Newly Diagnosed Mantle Cell Lymphoma

Qian Wang, Sicheng Ai, Tao You, Depei Wu, Haiwen Huang

Blood (2024) 144 (Supplement 1): 6296.

https://doi.org/10.1182/blood-2024-204476

Published: 2024

Journal Articles

Large-Scale Metabolomic Mendelian Randomization Analysis Identifies Pyridoxate As a Key Factor in Graft-Versus-Host Disease

Xinghao Yu, Yiyin Chen, Lei Lei, Dandan Lin, Ying Shen, Chang Hou, Jia Chen, Yi Fan, Huimin Lu, Depei Wu, Yang Xu

Blood (2024) 144 (Supplement 1): 3523.

https://doi.org/10.1182/blood-2024-206745

Published: 2024

Journal Articles

Short-Term Blinatumomab Prior to Allo-HSCT for High-Risk B-ALL

Huizhu Kang, Yuejun Liu, Ruju Wang, Meng Zhou, Chengyuan Gu, Xuefeng He, Jun Chen, Zhihong Lin, Depei Wu, Yue Han

Blood (2024) 144 (Supplement 1): 3494.

https://doi.org/10.1182/blood-2024-208142

Published: 2024

Journal Articles

Selective Histone Deacetylase Inhibitor Chidamide in Steroid Refractory Chronic Graft-Versus-Host Disease

Kangkang Lv, Yuejun Liu, Xuefeng He, Mingzhu Xu, Yuanyuan Du, Mimi Xu, Yue Han, Depei Wu

Blood (2024) 144 (Supplement 1): 7348.

https://doi.org/10.1182/blood-2024-209598

Published: 2024

Journal Articles

Efficacy and Safety of Venetoclax in Combination with Hypomethylating Agents for the Treatment of High-Risk Myelodysplastic Syndromes–Real-World Analyses

Jian Zhang, Yang Xu, Zhihong Lin, Jun Chen, Limin Liu, Depei Wu, Huiying Qiu

Blood (2024) 144 (Supplement 1): 6732.

https://doi.org/10.1182/blood-2024-199990

Published: 2024

Journal Articles

Subcutaneous Abatacept for Acute Graft-Versus-Host Disease Prophylaxis after Haploidentical Donor Hematopoietic Cell Transplantation: Efficacy, Safety, and Immunologic Effects

Yuhua Ru, Jinjin Zhu, Huanle Gong, Mimi Xu, Ying Wang, Miao Miao, Suning Chen, Xiang Zhang, Yi Fan, Yang Xu, Jia Chen, Depei Wu

Blood (2024) 144 (Supplement 1): 3515.

https://doi.org/10.1182/blood-2024-202490

Published: 2024

Journal Articles

VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial

Wei Cui, Xiaoqian Chen, Qingya Cui, Zheng Li, Sifan Chen, Mengyun Li, Xuekai Li, Juan Chen, Yan Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 3493.

https://doi.org/10.1182/blood-2024-207083

Published: 2024

Journal Articles

Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial

Yin Liu, Ye Zhao, Xiaofei Qi, Qiao Cheng, Jia Chen, Xiao Ma, Shengli Xue, Ying Wang, Xiaowen Tang, Huiying Qiu, Yang Xu, Depei Wu

Blood (2024) 144 (Supplement 1): 3535.

https://doi.org/10.1182/blood-2024-209696

Published: 2024

Journal Articles

Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

Yunju Ma, Qingya Cui, Chunxiu Yang, Wei Cui, Mengyun Li, Zheng Li, Haiping Dai, Liqing Kang, Lei Yu, Zaixiang Tang, Jianxin Fu, Min Jiang, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 683.

https://doi.org/10.1182/blood-2024-209249

Published: 2024

Journal Articles

A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment

Xiaodong Mo, He Huang, Feng Chen, Yi Luo, Jia Chen, Erlie Jiang, Yicheng Zhang, Linghui Xia, Chengwei Luo Luo, Xinchuan Chen, Nainong Li, Ming Jiang, Sujun Gao, Dongqin Yang, Qingli Zuo, Yimin Chen, Li Yao, Pan Liang, Depei Wu

Blood (2024) 144 (Supplement 1): 99.

https://doi.org/10.1182/blood-2024-193191

Published: 2024

Journal Articles

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 851.

https://doi.org/10.1182/blood-2024-201380

Published: 2024

Journal Articles

Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Blood (2024) 144 (Supplement 1): 305.

https://doi.org/10.1182/blood-2024-194716

Published: 2024

Journal Articles

Obinutuzumab Is a Promising Alternative for the Treatment of Relapsed or Refractory Autoimmune Hematological Disorders

Haiju He, Hong Tian, Yun Li, Ziqiang Yu, Depei Wu, Jie Yin

Blood (2024) 144 (Supplement 1): 3940.

https://doi.org/10.1182/blood-2024-210054

Published: 2024

Journal Articles

Efficacy and Safety Study of Chimeric Antigen Receptor-T Cell Therapy for People with Relapsed/Refractory Follicular Lymphoma

Ting Xu, Liangyu Zeng, Depei Wu, Caixia Li

Blood (2024) 144 (Supplement 1): 7801.

https://doi.org/10.1182/blood-2024-200310

Published: 2024

Journal Articles

Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial

Xiaoqian Chen, Wei Cui, Qingya Cui, Zheng Li, Sifan Chen, Mengyun Li, Xuekai Li, Juan Chen, Yan Yu, Xin Zhang, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 270.

https://doi.org/10.1182/blood-2024-209163

Published: 2024

Journal Articles

Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 399.

https://doi.org/10.1182/blood-2024-210100

Published: 2024

Journal Articles

Prospective Study of Avapritinib in Patients with Relapsed/Refractory or MRD-Positive Core-Binding Factor Acute Myeloid Leukemia with KIT Mutations

Xueqing Dou, Suning Chen, Depei Wu

Blood (2024) 144 (Supplement 1): 222.

https://doi.org/10.1182/blood-2024-207264

Published: 2024

NARROW

YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia

Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

Risk Factors and Prediction Model for Long-Term Survival of Ⅲ-Ⅵ Steroid-Refractory Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation

Preliminary Investigation of the Efficacy and Safety of Zanubrutinib in Combination with R-Chemo As First-Line Therapy Inpatients with Newly Diagnosed Mantle Cell Lymphoma

Large-Scale Metabolomic Mendelian Randomization Analysis Identifies Pyridoxate As a Key Factor in Graft-Versus-Host Disease

Short-Term Blinatumomab Prior to Allo-HSCT for High-Risk B-ALL

Selective Histone Deacetylase Inhibitor Chidamide in Steroid Refractory Chronic Graft-Versus-Host Disease

Efficacy and Safety of Venetoclax in Combination with Hypomethylating Agents for the Treatment of High-Risk Myelodysplastic Syndromes–Real-World Analyses

Subcutaneous Abatacept for Acute Graft-Versus-Host Disease Prophylaxis after Haploidentical Donor Hematopoietic Cell Transplantation: Efficacy, Safety, and Immunologic Effects

VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial

Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial

Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Obinutuzumab Is a Promising Alternative for the Treatment of Relapsed or Refractory Autoimmune Hematological Disorders

Efficacy and Safety Study of Chimeric Antigen Receptor-T Cell Therapy for People with Relapsed/Refractory Follicular Lymphoma

Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial

Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Prospective Study of Avapritinib in Patients with Relapsed/Refractory or MRD-Positive Core-Binding Factor Acute Myeloid Leukemia with KIT Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only